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Positive direct antiglobulin tests in patients with COVID-19 
COVID-19, the disease caused by the coronavirus, SARS-CoV-2, has now spread globally affecting 
more than 7 million people and resulting in over 400,000 deaths. In a recent meta-analysis there 
were slight differences in haemoglobin between patients with severe and non-severe disease 
(6.52g/L lower in severe disease), and between survivors and non-survivors (1.34g/L lower in non-
survivors),1 but haemolytic anaemia is not a feature of COVID-19, unless patients have developed 
disseminated intravascular coagulopathy or have an underlying haemolytic anaemia such as glucose-
6-phosphate dehydrogenase deficiency or a sickle cell disorder. Further, patients with COVID-19 are 
not at high risk of bleeding and therefore transfusion requirements for these patients do not appear 
to be any higher than patients without COVID-19.2 Positive direct antiglobulin tests [DAT] due to 
infections have been reported in pneumonia,3 hypergammaglobulinaemia4 and drug induced 
immune haemolytic anaemia, including in association with antibiotics.5 In this single large teaching 
hospital, we investigated the incidence and significance of DAT-positivity in patients with COVID-19.  
Full blood count samples were collected from 20 consecutive patients in the critical care unit with 
confirmed SARS-CoV-2 infection confirmed by RT-PCR. On the same day another 20 consecutive FBC 
samples were selected as controls from patients in the critical care unit who were confirmed to be 
negative for SARS-CoV-2 by RT-PCR on at least two occasions and who had no previous historical 
positive test. All samples had a DAT performed (BioRad IH-500 analyser, BioRad Diamed DC-
Screening I gels, DiaMed GmbH, Switzerland) and samples that were DAT-positive were further 
investigated using BioRad Diamed DC-Screening II gels, and were also eluted using the Gamma ELU-
KIT II kit (Immucor, Georgia, USA). The eluate was tested against A1- and B-cells and a three-cell red 
cell screening panel to establish if the IgG antibodies had any red cell antigen specificity. All washes 
for the elution were performed inside a microbiological safety cabinet at containment level 2. 
A 2 test was used to look for differences between groups with p values below 0.05 considered 
significant. 
The median age of the SARS-CoV-2 RT-PCR positive patients (patients) was 63 years (range 42-78 
years) and 54 years (range 22-77 years) for the SARS-CoV-2 RT-PCR negative patients (controls).  95% 
of patients were male, compared to 70% of controls (Table 1). In the patient group eight (40%) were 
group O, eight (40%) were group A, three (15%) were group B and one (5%) was group AB; in the 
control group 11 (55%) were blood group O, eight (40%) were blood group A, and one (5%) was 










This article is protected by copyright. All rights reserved.
Direct antiglobulin test was positive in 16/20 (80%) of patients compared with 7/20 (35%) of controls 
(significant difference, 2=8.29, p=0.004). Of the 16 patients that were DAT-positive, all (100%) were 
positive for IgG and one (6%) was also positive for C3d. Of the 7 controls who were DAT-positive, six 
(86%) were positive for IgG and none were positive for C3d. None of the eluted samples in either 
group showed specificity for red cell antigens in the three-cell screen or against A1 or B cells. 
There was no significant difference between the two groups for haemoglobin concentration 
(patients: median 88 g/L [95% confidence interval 82-93]; controls: 88 g/L [86-95]; p=0.348), bilirubin 
(patients: 6 µmol/L [5-12]; controls 10 µmol/L [7-15]; p=0.215) or LDH (patients: 389 U/L [343-432]; 
controls: 441 U/L [341-648]; p=0.167), and no patients or controls had morphological features of 
haemolysis. 
There was no significant difference between the number of patient (17/20 [85%]) or controls (12/20 
[60%]) who had been on antibiotics within the previous seven days (2=3.13, p=0.077), nor between 
the number of DAT positive samples on those patients and controls who had been on antibiotics 
(17/29) or those who had not (8/11) (2=0.68, p=0.410). 
There was no significant difference in the number of DAT-positive patients who were blood group A 
or AB (8/16) compared to controls (2/7) (2=0.910, p=0.340), and in the DAT-positive patients 13/16 
(81%) had not been transfused, compared to 4/7 (57%) of DAT-positive controls (not a significant 
difference, 2=1.467, p=0.226). 
Results of this study show that a high percentage of patients with COVID-19 are DAT-positive and all 
were positive by IgG, but these patients do not have any evidence of haemolytic anaemia and do not 
require more blood transfusion than patients who are not infected. No underlying antibody 
specificity for blood-group antigens was identified in the eluate, and there was no association with 
antibiotic usage. No patient had a positive antibody screen and the majority had not received a 
recent transfusion. These data indicate that DAT-positive results are likely to be due to SARS-CoV-2 
infection. The pathogenesis of the association is not yet clear, but is likely to be multifactorial. 
From the clinical transfusion perspective, it is important for laboratories to be aware of this finding, 
so that for patients who are SARSCoV-2 positive and DAT-positive, but have a negative antibody 
screen and no clinical features of haemolysis, further serological testing is not required. This will 
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Table 1. Summary of patient demographics and results SARS-CoV-2 positive patients. Median results 






 n=20 n=20 
Age, years [median (range)] 63 (42-78) 54 (22-77) 
Male [%] 95 70 
   
Blood Group [number (%)]   
Group O 8 (40%) 11 (55%) 
 O Rh(D) positive 8 10 
 O Rh(D) negative 0 1 
Group A 8 (40%) 8 (40%) 
 A Rh(D) positive 8 7 
 A Rh(D) negative 0 1 
Group B 3 (15%) 1 (5%) 
 B Rh(D) positive 3 1 
Group AB 1 (5%) 0 
 AB Rh(D) positive 1 0 
    
On antibiotics in last seven days [number (%)]* 17 (85%) 12 (60%) 
   
Haemoglobin, g/L [median (95% CI)] 88 (82-93) 88 (86-95) 
Bilirubin, µmol/L [median (95% CI)] 6 (5-12) 10 (7-15) 
Lactate Dehyrdogenase, U/L [median (95% CI)] 389 (343-432) 441 (341-648) 
   
Direct Antiglobulin Test Positive [number (%)] 16 (80%) 7 (35%) 
IgG positive 15 (94%) 6 (86%) 
IgG and C3d positive 1 (6%) 0 
IgG and C3d negative 0 1 (6%) 
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